Martin Parkhøi
@sneakview
Followers
84
Following
2K
Media
22
Statuses
851
Dad, Husbond, Investment Banker and double Danish Champion in marathon
Gentofte, Danmark
Joined September 2009
🫀 SELECT: Semaglutide’s Rapid Cardiovascular Benefits (data from #ECO2025) 🔹In adults with obesity & established CVD (no diabetes), semaglutide 2.4 mg weekly: 🔸⤵️ MACE by 41% within 6 months 🔹🕒 First significant benefit seen at day 20 🔸53% ↓ in 💔☠️, 43% ↓ in
3
58
133
This is how Ronald Reagan handles a question about being ‘too old’ for the presidency
302
905
9K
This should be illegal but it is standard operating procedure for PBMs. - North Carolina briefly exposed an analysis of the state gov's obesity med spending including rebates. - Novo Nordisk is paying rebates $663 to their PBM. - That's 49% of the retail price to the PBM. cc
2
7
16
Why did tirzepatide receive a rebrand for its obesity indication? According to this #STAT interview with Lilly CSO: —marketing —appease PBMs and insurers https://t.co/gcCN53OEm4
statnews.com
An interview with Eli Lilly’s chief scientist featured a discussion of new obesity drug data, gene editing, and a potential new heart drug.
2
1
11
All of the available preclinical data(and more to come) support #weightloss independent benefits of GLP-1RAs on CVD, inflammation, and metabolic liver disease. Weight loss helps, but it is not the only driver of benefit
9.4% mean weight loss is not much by today’s standard. Do you think GLP-1RAs have unique CV effects independent of weight loss/fat reduction? @AniaJastreboff @DanielJDrucker @ethanjweiss
4
13
60
Excellent 🧵! On first glance, my highlights: 👉Wow those curves separate early; is the protection #weightloss independent? 👉Curious @novonordiskus did not report breakdown for nonfatal MI and nonfatal stroke and that @NEJM did not ask for it 👉Remember these results apply to
📣#LBCT The SELECT trial 🟢 weekly Semaglutide 2.4 mg lead to a 20% reduction in the primary composite outcome of CV death, non-fatal MI & non-fatal stroke in patients with overweight or obesity, who DID NOT have diabetes! NNT= 67!!!! more trial details 👇 @cardionerds #AHA23
4
15
42
Coming up: and inside look at how Eli Lilly is ramping up manufacturing of Mounjaro to try to meet demand, ahead of expected approval this year in weight loss. Tune in! @CNNThisMorning
3
3
54
❗️SURPASS CVOT baseline characteristics out now❗️ 🔸Tirzepatide vs Dulaglutide : active comparator - a molecule with CV benefit 🔹Primary endpoint is non-inferiority BUT targeted to show superiority to (putative)placebo … win-win! 🔸Longest incretin CV trial 🔹1/3rd on SGLT-2i
1
22
55
GLP-1 based medicines and the treatment of #obesity How low can one go? @NatureMedicine
https://t.co/K0ciQTneA1
#weightloss
3
66
222
We project semaglutide 2.4 mg may benefit 93 million U.S. adults with overweight and obesity, resulting in 43 million fewer persons with obesity and 1.5 million fewer CVD events over 10 years with an estimated 18% risk reduction in those without prior CVD https://t.co/bHi4Bt94Ny
6
12
57
A comparison of SELECT and SURMOUNT-MMO designs🤗 SURMOUNT-MMO has broader inclusion criteria (incl. primary prevention) and adopted a 5-component primary endpoint (all-cause death, non-fatal MI, non-fatal stroke, coronary revascularization, HF event)
3
18
55
Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages via @ADA_Pubs
https://t.co/azArQhpjB0
diabetesjournals.org
Unexpected drug shortages of the long-acting glucagon-like peptide 1 (GLP-1) receptor agonists dulaglutide and semaglutide and the dual GLP-1/glucose-depen
0
11
22
SURMOUNT-3 Age 18 years or older, BMI ≥30 kg/m2,or ≥27 kg/m2 with at least 1 weight-related comorbidity: hypertension, dyslipidemia, OSA, or CVD. 12 weeks lifestyle intervention, inc 1,200-1,500 Kcal/day diet + #exercise then 72 wks Tirzepatide =26.6% #weightloss from baseline
1
2
12
With obesity rates on the rise in our country, we must do more to combat this epidemic head on. That’s why I introduced the Treat and Reduce Obesity Act alongside @SenBillCassidy in order to reduce the physical, social and financial costs of obesity.
6
19
63
As the magnitude of #weightloss achieved w GLP-1-based medicines continues to increase, more attention has shifted to "quality" of weight loss, preservation of lean mass and muscle strength, with consideration of sarcopenic #obesity Yet to date, physical activity improves in most
5
32
158
@EMA_News The post-bariatric surgery suicide event rate in a meta-analysis was 2.7/1000 patients while the suicide/self-harm attempt event rate was 17/1000 patients compared to age-, sex-, and BMI-matched controls
link.springer.com
Obesity Surgery - Bariatric surgery is endorsed by multiple societies as the most effective treatment for obesity. Psychosocial functioning has also been noted to improve for most patients after...
0
1
5
If you think suicidal thoughts are bad, it's worth remembering that bariatric surgery carries a 0.3% risk of actual death within 30 days of surgery
pubmed.ncbi.nlm.nih.gov
This study confirms the low 30-day mortality rate following bariatric surgery. The recognized complications of anastomotic leak, cardiac events, and pulmonary emboli accounted for the majority of...
As the new more powerful GLP-1RAs become more widely used for #weightloss in PPL with #obesity one can expect increased scrutiny of rare CNS AEs. Rigorous case-control real world data will be helpful together with large RCT safety trials like SELECT
4
2
18
100 years after discovery of glucagon, the excitement builds for glucagon-GLP-1 multi-agonists inc Pemvidutide, Survoditide and Retatrutide #ADA2023 Yet other GCG-GLP-1 co-agonists exhibit cardiovascular, hematopoietic, and inflammation signals in humans https://t.co/cxKjOgwVhe
2
15
59